ATC Group: V09A Central nervous system

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of V09A in the ATC hierarchy

Level Code Title
1 V Various
2 V09 Diagnostic radiopharmaceuticals
3 V09A Central nervous system

Group V09A contents

Code Title
V09AA Technetium (99mTc) compounds
V09AB Iodine (123I) compounds
V09AX Other central nervous system diagnostic radiopharmaceuticals

Active ingredients in V09A

Active Ingredient Description
Florbetaben ¹⁸F

Florbetaben ¹⁸F binds to β-amyloid neuritic plaques in the brain. It is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment.

Florbetapir ¹⁸F

Florbetapir ¹⁸F binds to β-amyloid plaques and the ¹⁸F isotope produces a positron signal that is detected by a PET scanner. Florbetapir ¹⁸F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.

Flutemetamol ¹⁸F

Flutemetamol ¹⁸F binds to β-amyloid neuritic plaques in the brain. It is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. VIZAMYL should be used in conjunction with a clinical evaluation.

Ioflupane ¹²³I

Ioflupane ¹²³I is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian syndromes (PS).

Technetium ⁹⁹ᵐTc bicisate
Technetium ⁹⁹ᵐTc exametazime

When technetium Tc 99m pertechnetate is added to exametazime in the presence of stannous reductant, a lipophilic technetium Tc 99m complex is formed. This lipophilic complex is the active moiety. The lipophilic technetium Tc 99m exametazime complex is taken up and retained in leukocytes. It is used for leukocyte (white blood cell) labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.

Related product monographs

Title Information Source Document Type  
AMYVID Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
CELSUNAX Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
CERETEC Powder for solution for injection FDA, National Drug Code (US) MPI, US: SPL/Old
DATSCAN Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
NEURACEQ Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
STRIASCAN Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
ULTRA-TECHNEKOW FM Radionuclide generator Health Products Regulatory Authority (IE) MPI, EU: SmPC
VIZAMYL Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR